153 related articles for article (PubMed ID: 29121476)
1. Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies.
Williamson B; Riley RJ
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1237-1250. PubMed ID: 29121476
[TBL] [Abstract][Full Text] [Related]
2. Studying the right transporter at the right time: an
Elsby R; Atkinson H; Butler P; Riley RJ
Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):619-655. PubMed ID: 36205497
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
Feng B; Varma MV; Costales C; Zhang H; Tremaine L
Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
[TBL] [Abstract][Full Text] [Related]
4. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
Varma MV; El-Kattan AF
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
[TBL] [Abstract][Full Text] [Related]
5. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
Li R; Barton HA; Varma MV
Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
[TBL] [Abstract][Full Text] [Related]
6. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.
Barton HA; Lai Y; Goosen TC; Jones HM; El-Kattan AF; Gosset JR; Lin J; Varma MV
Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):459-72. PubMed ID: 23331046
[TBL] [Abstract][Full Text] [Related]
7. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions.
Taskar KS; Harada I; Alluri RV
Curr Drug Metab; 2021; 22(7):523-531. PubMed ID: 33397250
[TBL] [Abstract][Full Text] [Related]
9. Effects of Drug Transporters on Pharmacological Responses and Safety.
Liu CX; Yi XL; Fan HR; Wu WD; Zhang X; Xiao XF; He X
Curr Drug Metab; 2015; 16(9):732-52. PubMed ID: 26630905
[TBL] [Abstract][Full Text] [Related]
10. Dealing with the complex drug-drug interactions: towards mechanistic models.
Varma MV; Pang KS; Isoherranen N; Zhao P
Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
[TBL] [Abstract][Full Text] [Related]
11. Hepatic drug transporters: the journey so far.
Riley RJ; Foley SA; Barton P; Soars MG; Williamson B
Expert Opin Drug Metab Toxicol; 2016; 12(2):201-16. PubMed ID: 26670591
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
Feng B; Varma MV
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
[TBL] [Abstract][Full Text] [Related]
13. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
Patel M; Taskar KS; Zamek-Gliszczynski MJ
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S23-39. PubMed ID: 27385177
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance.
Liang X; Lai Y
Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):869-886. PubMed ID: 33793347
[No Abstract] [Full Text] [Related]
15. Role of Hepatic Drug Transporters in Drug Development.
Liu H; Sahi J
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S11-22. PubMed ID: 27385168
[TBL] [Abstract][Full Text] [Related]
16. Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.
Kimoto E; Obach RS; Varma MVS
Drug Metab Pharmacokinet; 2020 Feb; 35(1):18-29. PubMed ID: 31952912
[TBL] [Abstract][Full Text] [Related]
17. Beyond the ITC White Paper: emerging sciences in drug transporters and opportunities for drug development.
Lai Y; Hsiao P
Curr Pharm Des; 2014; 20(10):1577-94. PubMed ID: 23789952
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development.
Lu C; Di L
Biopharm Drug Dispos; 2020 Feb; 41(1-2):3-31. PubMed ID: 31778578
[TBL] [Abstract][Full Text] [Related]
19. Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model.
Asano S; Kurosaki C; Mori Y; Shigemi R
Drug Metab Pharmacokinet; 2024 Feb; 54():100531. PubMed ID: 38064927
[TBL] [Abstract][Full Text] [Related]
20. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.
Chu X; Chan GH; Evers R
J Pharm Sci; 2017 Sep; 106(9):2357-2367. PubMed ID: 28416420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
